). BMP-4 not only governs the 14 pituitary organogenesis but also plays a key role in the pathogenesis of differentiated 15 pituitary lineages (Giacomini et al., 2006; Labeur et al., 2010; Tsukamoto et al., 2010) . 16 Dopamine agonists (DA) are the clinical treatment of choice for prolactin 17 (PRL)-secreting pituitary adenomas (Casanueva et al., 2006) . They control PRL secretion and cell proliferation by interacting with the dopamine D2 receptor (D2R), 1 which subsequently activates various transduction pathways (Missale et al., 1998) . 2 D2R agonists are efficient in the majority of cases; however, some patients with 3 prolactinomas fail to obtain PRL normalization and reduction in tumor size even with 4 the most potent dopamine agonist, cabergoline (Molitch, 2005; Gillam et al., 2006; 5 Hofland et al., 2010) . These prolactinomas, resistant to DA, are usually large and/or 6 invasive, and surgery therefore cannot be a complete curative treatment. In such 7 tumors poorly or partially responsive to DA, an alternative medical treatment is needed. 8 Experimental data have demonstrated that different somatostatin receptor (SSTR) 9 subtypes are expressed at various levels in prolactinomas, SSTR-5 being the most 10 important in the regulation of PRL secretion (Shimon et al., 1997; Jaquet et al., 1999) .
11
A partial synergistic effect between D2R and SSTR-5 in suppressing PRL secretion has 12 also been reported (Jaquet et al., 1999) .
13
Here we studied a unique activity of the pituitary BMP system in PRL 14 regulation by somatostatin analogs using rat somato-lactotropinoma GH3 cells. GH3 15 cells express somatostatin receptors including SSTR-1, -2, -3, -4 and -5 as well as 16 dopamine D2R (Johnston et al., 1991; Yang et al., 2005; Miyoshi et al., 2008) . In 17 addition, we earlier reported that both GH3 cells and rat whole pituitaries express BMP/activin type I receptors (ALK-2, -3 and -4), type II receptors (ActRII, ActRIIB 1 and BMPRII) and Smads (Smad1, 2, 3, 4, 5, 6, 7 and 8) (Miyoshi et al., 2008) . The 2 whole pituitary tissues also express BMP/activin ligands, including 3 activinβA/βB, and inhibinα subunits. The predominant BMP ligands endogenously 4 expressed in GH3 cells are reported to be BMP-4 and BMP-6 (Miyoshi et al., 2008 Noggin. After 24-h culture, the medium removed from the cells was centrifuged.
14 The supernatant of the culture media was collected and stored at -80°C until assay.
15
The levels of PRL in the cultured media were determined by a rat-specific enzyme 16 immunoassay with assay sensitivity of 1 pg/ml (Duhau et al., 1991) (SPI-BIO, 17 Montigny-le-Bretonneux, France). The intra-and inter-assay coefficients are 10.6% and 13.4%, respectively. We first examined the effects of BMPs on PRL secretion by GH3 cells for 24 OCT had no effects on PRL and cAMP release, while SOM and BRC suppressed PRL 10 and cAMP levels (Fig. 1B) . To clarify the effects of OCT, SOM and BRC on PRL 11 secretion by GH3 cells, GH3 cells were cultured in the presence of forskolin (FSK).
12
FSK significantly activated PRL secretion with increasing cAMP level (Fig. 1C) .
13
OCT had no effect on FSK-induced PRL or cAMP level, whereas SOM showed a 14 dose-responsive decrease of PRL as well as cAMP level (Fig. 1C) . BRC showed more 15 efficacious suppression of FSK-induced PRL secretion as well as cAMP level. not affected by addition of Noggin. These findings suggest that the endogenous BMP 10 system is active to modulate OCT and SOM actions for regulating PRL secretion in 11 GH3 cells.
12
We also investigated the effects of BMP-4 and Noggin on PRL mRNA levels 13 in GH3 cells treated with FSK (Fig. 3) further suppressed by BMP-4 (Fig. 3) . then treated with BMP-4 (10-100 ng/ml), BMP-6 (10-100 ng/ml) and Noggin (10-100 5 ng/ml). After 24-h culture, the supernatants of culture media were collected, and 6 prolactin (PRL) and cAMP levels were determined by specific enzyme immunoassays. 
